AAD
  • Registration
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Topics
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Resources
  • Registration
Facebook iconInstagram iconTwitter icon
Jul 05, 2022

AbbVie: Challenging AD Expectations: A Therapy Option That Challenges Treatment Goals for Patients With Refractory, Moderate to Severe Atopic Dermatitis (AD) Who Are Not Adequately Controlled With Other Systemic Drug Products

Thursday, July 21


Aadia22 Ind High Graphic

The goals of this program are to understand the burden of AD, to discuss the efficacy and safety of RINVOQ in patients with moderate to severe AD, and to review resources available through RINVOQ Complete.

When: Thursday, July 21 | 7 p.m. Registration and Meal | 7:30 p.m. Program

Where: Room 118/119 | Vancouver Convention Centre

Interesting Stories
What makes a biosimilar and an Interchangeable biosimilar different?
Presented by Boehringer Ingelheim
What makes a biosimilar and an Interchangeable biosimilar different?
Janssen-Sponsored Symposium
Presented by Janssen Biotech, Inc.
Janssen-Sponsored Symposium
Prurigo Nodularis and Atopic Dermatitis:
Presented by Sanofi and Regeneron Pharmaceuticals, Inc.
Prurigo Nodularis and Atopic Dermatitis:
Advancing Therapeutic Conversations
Presented by AbbVie
Advancing Therapeutic Conversations
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Presented by Neutrogena
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Join Us to Learn More About SOTYKTU<sup>TM</sup> (deucravacitinib):
Presented by Bristol Myers Squibb
Join Us to Learn More About SOTYKTUTM (deucravacitinib):
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Presented by Pfizer Inc.
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
More in 2022 AAD Innovation Academy
Keira L. Barr, MD, FAAD
2022 AAD Innovation Academy
Unlocking the secrets of mind-body therapy
Jul 29, 2022
Robert T. Brodell, MD, FAAD
2022 AAD Innovation Academy
Fox Lecture: Access belongs to everyone
Jul 29, 2022
Img 9508
2022 AAD Innovation Academy
AAD debuts Innovation Academy in Vancouver
Jul 29, 2022
Edit Olasz Harken, MD, PhD, FAAD
2022 AAD Innovation Academy
Your name can be your skin care brand
Jul 29, 2022
Pearl E. Grimes, MD, FAAD
2022 AAD Innovation Academy
Kelly Lectureship traces advances in pigmentary diseases
Jul 29, 2022
Pearl Grimes, MD, FAAD, and Robert T. Brodell, MD, FAAD, FRCP
2022 AAD Innovation Academy
Saturday’s named lectureships take the stage
Jul 23, 2022
Jason B. Lee, MD, FAAD
2022 AAD Innovation Academy
How are your diagnostic skills?
Jul 23, 2022
Lindsay Strowd, MD, FAAD
2022 AAD Innovation Academy
Consultive dermatology plugs in post pandemic
Jul 23, 2022
Mehdi Rashighi, MD, FAAD
2022 AAD Innovation Academy
Game-changing new treatments evolve for dermatologic conditions
Jul 23, 2022
Carolyn Goh, MD, FAAD
2022 AAD Innovation Academy
New approaches to managing hair disorders
Jul 23, 2022
So Yeon Paek, MD, FAAD
2022 AAD Innovation Academy
Laser focused
Jul 22, 2022
Brett A. King, MD, PhD, FAAD
2022 AAD Innovation Academy
JAK inhibitors revolutionize dermatology
Jul 22, 2022
AAD
Facebook iconInstagram iconTwitter icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.